Keratitis (Ophthalmology) - Drugs In Development, 2021

August 2021 | 105 pages | ID: K24FD2F1A46BEN
Global Markets Direct

Abstracts

Keratitis (Ophthalmology) - Drugs In Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Keratitis - Drugs In Development, 2021, provides an overview of the Keratitis (Ophthalmology) pipeline landscape.Keratitis is an inflammation of the cornea. Symptoms include eye redness, eye pain, blurred vision, decreased vision and sensitivity to light. Risk factors include virus infections, injury, climatic condition and reduced immunity.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Keratitis - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Keratitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Keratitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Keratitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages are 1, 4, 3, 1, 14 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively.

Keratitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Keratitis (Ophthalmology).
• The pipeline guide reviews pipeline therapeutics for Keratitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Keratitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Keratitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Keratitis (Ophthalmology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Keratitis (Ophthalmology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Keratitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Keratitis - Overview
Keratitis - Therapeutics Development
Keratitis - Therapeutics Assessment
Keratitis - Companies Involved in Therapeutics Development
Keratitis - Drug Profiles
Keratitis - Dormant Projects
Keratitis - Discontinued Products
Keratitis - Product Development Milestonesh
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Keratitis, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Keratitis - Pipeline by Alfasigma SpA, 2021
Keratitis - Pipeline by AmebaGone Inc, 2021
Keratitis - Pipeline by Claris Biotherapeutics Inc, 2021
Keratitis - Pipeline by Cumulus Pharmaceutical LLC, 2021
Keratitis - Pipeline by Dobecure SL, 2021
Keratitis - Pipeline by Editas Medicine Inc, 2021
Keratitis - Pipeline by EyeGate Pharmaceuticals Inc, 2021
Keratitis - Pipeline by Fox Chase Chemical Diversity Center Inc, 2021
Keratitis - Pipeline by iVeena Delivery Systems Inc, 2021
Keratitis - Pipeline by Knight Therapeutics Inc, 2021
Keratitis - Pipeline by MimeTech Srl, 2021
Keratitis - Pipeline by NanoViricides Inc, 2021
Keratitis - Pipeline by Neuroptika Inc, 2021
Keratitis - Pipeline by Oyster Point Pharma Inc, 2021
Keratitis - Pipeline by Provectus Biopharmaceuticals Inc, 2021
Keratitis - Pipeline by RegeneRx Biopharmaceuticals Inc, 2021
Keratitis - Pipeline by Riptide Bioscience Inc, 2021
Keratitis - Pipeline by Shanghai Bendao Gene Technology Co Ltd, 2021
Keratitis - Pipeline by Shenyang Sinqi Pharmaceutical Co Ltd, 2021
Keratitis - Pipeline by Shulov Innovative Science Ltd, 2021
Keratitis - Pipeline by Sinsa Labs Inc, 2021
Keratitis - Pipeline by TGV-Inhalonix Inc, 2021
Keratitis - Pipeline by Veloce BioPharma LLC, 2021
Keratitis - Pipeline by Viraze, 2021
Keratitis - Pipeline by Zylem Biosciences Inc, 2021
Keratitis - Dormant Projects, 2021
Keratitis - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Keratitis, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Top 10 Routes of Administration, 2021
Number of Products by Stage and Top 10 Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021